Cyclacel Pharmaceuticals (NASDAQ:CYCC) Receives New Coverage from Analysts at StockNews.com

StockNews.com started coverage on shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC) in a report published on Sunday. The firm issued a hold rating on the biotechnology company’s stock.

Separately, Roth Mkm cut their price objective on shares of Cyclacel Pharmaceuticals from $21.00 to $11.00 and set a buy rating for the company in a research report on Friday, May 3rd.

Cyclacel Pharmaceuticals Stock Performance

CYCC stock opened at $2.05 on Friday. The company’s 50-day simple moving average is $2.10 and its 200 day simple moving average is $2.83. Cyclacel Pharmaceuticals has a 52 week low of $1.30 and a 52 week high of $13.20. The company has a market capitalization of $2.99 million, a PE ratio of -0.09 and a beta of 0.54.

Cyclacel Pharmaceuticals (NASDAQ:CYCC) last released its quarterly earnings results on Tuesday, May 14th. The biotechnology company reported ($2.27) EPS for the quarter, beating the consensus estimate of ($4.93) by $2.66. Cyclacel Pharmaceuticals had a negative net margin of 4,401.34% and a negative return on equity of 1,009.04%. The business had revenue of $0.03 million for the quarter. During the same quarter last year, the company posted ($7.05) earnings per share. On average, analysts forecast that Cyclacel Pharmaceuticals will post -6.32 EPS for the current year.

Cyclacel Pharmaceuticals Company Profile

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors.